Drug intelligence / Profile preview

paromomycin

Development stage
Approved
Lead developer
Streptomyces
Modality
Small Molecules
Administration
Oral, Intramuscular, Topical
01

Overview

Paromomycin is an aminoglycoside antibiotic produced by various Streptomyces species. It is primarily used to treat acute and chronic intestinal amebiasis, as well as other intestinal parasitic infections such as giardiasis, cryptosporidiosis, and tapeworm infections. It is also used as adjunctive therapy in the management of hepatic coma due to its ability to reduce ammonia-producing gut bacteria. The drug acts by binding to the 16S rRNA of the bacterial ribosome, inhibiting protein synthesis and leading to cell death in susceptible organisms. It has poor oral absorption, so its effects are largely confined to the gastrointestinal tract[1][2][3][6].

Brand names
HumatinGabbroralAmeparomoLumenexParofor (veterinary)Aminosidine
Other names
AminosidinAminosidineCatenulinCrestomycinEstomycinHydroxymycinMonomycin ANeomycin EParomomicinaParomomycin IParomomycineParomomycinumPaucimycinPaucimycinumZygomycin A1
02

Targets

30S A-site (Bacterial ribosomal 30S A-site)18S rRNA (18S ribosomal RNA)

Beyond the preview

Go deeper on paromomycin.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Full profile access

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Full profile access

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Full profile access

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Full profile access

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Full profile access

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on paromomycin.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call